Business Standard

Alembic: Prospects sound, but investors should await a better entry point

Higher capex and depreciation post commercialisation, increased operating costs as well as interest costs are expected to hit the company's FY22 earnings

medicine, drugs, pharma
Premium

While there has been a bit of a dip in the stock, most brokerages believe that the long term growth story is intact

Ram Prasad Sahu New Delhi
After hitting its 52-week high last week, the stock of Alembic Pharmaceuticals shed about 4 per cent. The company has announced that it is raising Rs 1,200 crore through a qualified institutional placement (QIP) to reduce debt and fund its expansion plans. 

The equity infusion is expected to lead to a dilution of 6.4 per cent. Higher capex and depreciation, and increased operating costs, as well as interest costs, are expected to hit the firm’s FY22 earnings. Though there will be equity dilution, part of this may get offset by lower interest cost as the company is planning to pay up

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 27 2020 | 7:00 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com